Ablynx is a biopharmaceutical company engaged in the discovery and development of Nanobodies, a novel class of therapeutic proteins based on single-domain antibody fragments, for a range of serious human diseases, including inflammation, haematology, oncology and pulmonary disease.
Ablynx today announced that it has been awarded a €2.1 million grant by the Flemish Agency for Innovation by Science and Technology (IWT) to help advance a wholly-owned programme, which will explore a novel approach to the treatment of diseases of the eye by utilising some of the unique characteristics of Nanobodies. The grant is available over a period of three years and will allow the development and subsequent testing of Nanobody leads in relevant pre-clinical disease models.
Dr Tony De Fougerolles, CSO of Ablynx, commented:
“This grant is a further clear endorsement of the innovative potential of the Nanobody platform and its ability to generate differentiated drugs in disease areas which are scientifically challenging and which represent a high unmet medical need. Ophthalmology is an increasingly important area for many pharmaceutical companies as they seek to meet the demands of an ageing population.